Eclipse named as likely target for TMR (transmyocardial revascularisation) panel review
This article was originally published in Clinica
Eclipse Surgical Technologies will probably undergo an FDA panel review in the US next month for its transmyocardial revascularisation (TMR) device. The company emerged as the most likely subject of an October 27 meeting announced last week by the FDA. Shares in the company rose by nearly 27% on the day of the announcement.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.